Continuous Theta Burst Stimulation for Generalized Anxiety Disorder
Key facts
- Who runs it
- Military Hospital 175
- Where
- Vietnam1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 9 Sept 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Continuous Theta Burst Stimulation of the Right Posterior Parietal Cortex
- Continuous Theta Burst Stimulation of the Right Dorsolateral Prefrontal Cortex
- Record updated
- 10 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Age 18 to 65 years
- Right-handed
- Diagnosis of generalized anxiety disorder (GAD) according to ICD-10 criteria (F41.1), confirmed by a psychiatrist
- GAD must be the primary diagnosis and the main reason for treatment at the time of enrollment. Current or past comorbid major depressive disorder will be identified and recorded
- Hamilton Anxiety Rating Scale (HAM-A) total score >18 at screening/baseline
- Able and willing to provide written informed consent and comply with essential study procedures
- Participants may be psychotropic-medication naïve or may be receiving psychotropic medication. Participants currently receiving psychotropic medication must have maintained the same medication(s) and dose(s) for at least 2 weeks before randomization; for fluoxetine, the required stable period is at least 4 weeks
Who cannot take part
- Intracranial or head/neck metallic foreign bodies or implants that constitute a contraindication to TMS or MRI
- Alcohol or substance abuse or dependence within the previous 6 months
- Implanted electronic devices such as a cardiac pacemaker, implantable cardioverter-defibrillator, or deep brain stimulator
- History of epilepsy or seizures, except febrile seizures in childhood
- Bipolar disorder
- Other major psychiatric disorders, including schizophrenia, delusional disorder, or eating disorders
- A medical condition associated with a high seizure risk or a history of cranial surgery
- Current use of medication judged by the screening physician to substantially increase seizure risk, or rapid reduction/discontinuation of benzodiazepines, antiseizure medications, or other centrally acting medications associated with withdrawal or increased seizure risk
- Elevated C-reactive protein associated with clinically significant acute infection or acute inflammatory illness that, in the investigator's judgment, may affect participant safety or study outcome assessment
- Unable to understand or complete essential study procedures. Participants with potentially reversible temporary exclusion conditions may be rescreened once the condition has been adequately corrected or clinically stabilized
- Serum vitamin D level <20 ng/mL that has not been adequately corrected
- Untreated or clinically unstable thyroid dysfunction based on abnormal TSH and/or free T4 levels
- Clinically significant intracranial structural abnormalities that may affect TMS safety, neuropsychiatric presentation, or study neurophysiological measures
- Acute suicide risk, including clear suicidal ideation or behavior
- Pregnant or breastfeeding
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Generalized anxiety disorder
This trial is currently available in Vietnam.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This randomized, rater-blinded clinical trial evaluates the effectiveness, safety, and tolerability of continuous theta burst stimulation (cTBS) in adults with generalized anxiety disorder (GAD). Participants will be randomly assigned in a 1:1 ratio to receive cTBS targeting either the right posterior parietal cortex (R-PPC) or the right dorsolateral prefrontal cortex (R-DLPFC). Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria.
Read full original descriptionShow less
The primary objective is to compare changes in anxiety symptom severity, measured using the Hamilton Anxiety Rating Scale (HAM-A), from baseline to the end-of-treatment assessment. Secondary and exploratory assessments include treatment response and remission, quality of life, sleep quality, cognitive function, safety and tolerability, resting electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).
The 2 groups in the trial
- cTBS Right Posterior Parietal CortexTreatment being tested
Participants receive continuous theta burst stimulation (cTBS) targeting the right posterior parietal cortex (R-PPC). Treatment is delivered at 80% of the resting motor threshold (RMT), with 600 pulses per session. Participants receive two sessions per treatment day, separated by 30 ± 5-minute intervals, for a total of 10 sessions over approximately 1 week. Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria.
Treatment: Continuous Theta Burst Stimulation of the Right Posterior Parietal Cortex
- cTBS Right Dorsolateral Prefrontal CortexTreatment being tested
Participants receive continuous theta burst stimulation (cTBS) targeting the right dorsolateral prefrontal cortex (R-DLPFC). Treatment is delivered at 100% of the resting motor threshold (RMT), with 600 pulses per session. Participants receive one session per treatment day, 5 days per week for 4 weeks, for a total of 20 sessions. Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria.
Treatment: Continuous Theta Burst Stimulation of the Right Dorsolateral Prefrontal Cortex
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Rater-Blinded Trial Comparing Continuous Theta Burst Stimulation Targeting the Right Posterior Parietal Cortex and Right Dorsolateral Prefrontal Cortex for Generalized Anxiety Disorder
- Criteria questions
- Built from NCT07770919, who can take part
- Record updated
- 10 September 2026